Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study.

Qing Wei(Chinese Academy of Sciences), Jingjing Li(Zhejiang Cancer Hospital), Zhiyuan Hu(Fujian Medical University), Cong Luo(Central South University), Lei Chen(Zhuzhou Central Hospital), Qi Xu(China Jiliang University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanlian Yang(National Center for Nanoscience and Technology), Yankun Li(Guangdong Medical College)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.e16094
Cited by 0

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412